Why the study?
High-grade serous ovarian cancer is fatal, and a systematic analysis of differentially expressed genes to screen and detect significant prognostic biomarkers was lacking.
Does high expression of FAP predict poor overall and progression-free survival in patients with high-grade serous ovarian cancer?
Does high expression of FAP predict poor overall and progression-free survival in patients with high-grade serous ovarian cancer?
High-level expression of FAP is a potential prognostic biomarker associated with poor survival outcomes in high-grade serous ovarian cancer.
FAP expression may serve as a prognostic biomarker in HGSOC; leaves open validation and therapeutic targeting in prospective studies.
BACKGROUND: High-grade serous ovarian cancer (HGSOC) is a fatal form of ovarian cancer. Previous studies indicated some potential biomarkers for clinical evaluation of HGSOC prognosis. However, there is a lack of systematic analysis of different expression genes (DEGs) to screen and detect significant biomarkers of HGSOC. METHODS: TCGA database was conducted to analyze relevant genes expression in HGSOC. Outcomes of candidate genes expression, including overall survival (OS) and progression-free survival (PFS), were calculated by Cox regression analysis for hazard rates (HR). Histopathological investigation of the identified genes was carried out in 151 Chinese HGSOC patients to validate gene expression in different stages of HGSOC. RESULTS: Of all 57,331 genes that were analyzed, FAP was identified as the only novel gene that significantly contributed to both OS and PFS of HGSOC. In addition, FAP had a consistent expression profile between carcinoma-paracarcinoma and early-advanced stages of HGSOC. Immunological tests in paraffin section also confirmed that up-regulation of FAP was present in advanced stage HGSOC patients. Prediction of FAP network association suggested that FN1 could be a potential downstream gene which further influenced HGSOC survival. CONCLUSIONS: High-level expression of FAP was associated with poor prognosis of HGSOC via FN1 pathway.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: